NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.94M | 1.94M | 2.01M | 1.25M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.57M | 5.49M | 4.59M | 4.48M | 4.28M |
| Operating Income | -8.57M | -5.49M | -4.59M | -4.48M | -4.28M |
| Income Before Tax | 7.80M | -1.22M | -19.30M | -3.02M | -6.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.80M | -1.22M | -19.30M | -3.02M | -6.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.80M | -1.22M | -19.30M | -3.02M | -6.50M |
| EBIT | -8.57M | -5.49M | -4.59M | -4.48M | -4.28M |
| EBITDA | -8.56M | -5.48M | -4.58M | -4.47M | -4.27M |
| EPS Basic | 0.08 | -0.02 | -0.26 | -0.04 | -0.09 |
| Normalized Basic EPS | 0.05 | -0.01 | -0.16 | -0.03 | -0.06 |
| EPS Diluted | -0.09 | -0.07 | -0.26 | -0.04 | -0.09 |
| Normalized Diluted EPS | 0.05 | -0.01 | -0.16 | -0.03 | -0.06 |
| Average Basic Shares Outstanding | 92.44M | 79.90M | 73.51M | 73.16M | 71.96M |
| Average Diluted Shares Outstanding | 105.10M | 80.86M | 73.51M | 73.16M | 71.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |